NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...
Guerbet's innovation, Eluciremâ„¢ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results